Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3121 |
Name | gallbladder cancer |
Definition | A biliary tract cancer that is located_in the gallbladder. |
Source | DiseaseOntology.org |
Alt Ids | DOID:8090 DOID:8157 |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer gallbladder cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF L485W | Ulixertinib | gallbladder cancer | sensitive | detail... |
BRAF D594N | Binimetinib + Encorafenib | gallbladder cancer | predicted - sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | gallbladder cancer | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | gallbladder cancer | sensitive | detail... |
MLH1 negative | Pembrolizumab | gallbladder cancer | sensitive | detail... |
MSH6 negative | Pembrolizumab | gallbladder cancer | sensitive | detail... |
RET fusion | Pralsetinib | gallbladder cancer | sensitive | detail... |
RET fusion | Selpercatinib | gallbladder cancer | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | gallbladder cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | ROU | POL | ITA | BGR | 0 |
NCT02520141 | Phase II | Ramucirumab | Ramucirumab for Advanced Pre-treated Biliary Cancers | Completed | USA | 0 |
NCT02632305 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel | A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) | Active, not recruiting | CAN | 0 |
NCT02711553 | Phase II | Ramucirumab Merestinib Cisplatin + Gemcitabine | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Active, not recruiting | USA | TUR | SWE | HUN | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG | 4 |
NCT03093870 | Phase II | Capecitabine + Varlitinib Capecitabine | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | Completed | USA | POL | HUN | ESP | AUS | 6 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG | 6 |
NCT04003636 | Phase III | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) | Active, not recruiting | USA | TUR | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
NCT04057365 | Phase II | DKN-01 + Nivolumab | A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | Terminated | USA | 0 |
NCT04306367 | Phase II | Olaparib + Pembrolizumab | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | Active, not recruiting | USA | 0 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | DNK | 3 |
NCT04466891 | Phase II | ZW25 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01) | Completed | USA | ITA | GBR | FRA | ESP | CAN | 3 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04781192 | Phase Ib/II | Durvalumab + Regorafenib | The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers | Recruiting | USA | 0 |
NCT04907851 | Phase II | Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 | A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) | Completed | GBR | AUS | 0 |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
NCT04976634 | Phase II | Belzutifan + Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Recruiting | USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS | 2 |
NCT05000294 | Phase Ib/II | Atezolizumab + Tivozanib | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Recruiting | USA | 0 |
NCT05506943 | Phase II | Paclitaxel CTX-009 + Paclitaxel | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers | Active, not recruiting | USA | 0 |
NCT05564403 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | Recruiting | USA | 0 |
NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Recruiting | USA | CAN | 0 |
NCT06178445 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab + Trastuzumab | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC) | Recruiting | DEU | 0 |
NCT06282575 | Phase III | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + ZW25 Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + ZW25 Cisplatin + Gemcitabine + ZW25 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Recruiting | USA | ITA | ISR | ESP | CAN | ARG | 8 |
NCT06360354 | Phase I | AMG193 + Cisplatin + Gemcitabine + Pembrolizumab AMG193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AMG193 + Gemcitabine + Nab-paclitaxel | A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion | Recruiting | USA | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 2 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |